Current And Novel Approaches To The Treatment Of Head And Neck Cancer
Full Disclosure Policy Affecting CE Activities:
As a sponsor accredited by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:
Susannah Motl, PharmD
Department of Pharmacy
University of Tennessee College of Pharmacy
• Dr Motl reports receiving funding for phase I clinical trials for GlaxoSmithKline; and serving on the speakers' bureau for Amgen Inc.
Barry R. Goldspiel, PharmD, BCPS, BCOP, FASHP
Projects Coordinator Pharmacist
Oncology Clinical Pharmacy Specialist
Specialized Residency in Oncology Pharmacy Practice
National Institutes of Health Clinical Center
• Dr Goldspiel reports having no significant financial or advisory relationships with corporate organizations related to this activity.
Patrick J. Medina, PharmD, BCOP
Department of Pharmacy
Clinical and Administrative Sciences
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma
• Dr Medina reports serving on the speakers' bureaus for Amgen Inc. and Genentech, Inc.
Rowena N. Schwartz, PharmD, BCOP
Associate Professor and Vice Chair
Pharmacy and Therapeutics
University of Pittsburgh School of Pharmacy
University of Pittsburgh Cancer Institute
• Dr Schwartz reports serving on the speakersÕ bureaus for Genentech, Inc., MGI, and Merck & Co, Inc.; and serving on the advisory boards for Genentech, Inc. and MGI.
Notice: In accordance with the ACPE Criteria for Quality, the audience is advised that articles in this continuing pharmaceutical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.
Dr Motl—celecoxib, cetuximab, gefitinib, palifermin.
Dr Medinabevacizumab, erlotinib, cetuximab.
All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.
University of Tennessee Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. University of Tennessee Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.